Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE NITRATE COMBINATION PACK versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE NITRATE COMBINATION PACK versus NILSTAT.
MICONAZOLE NITRATE COMBINATION PACK vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole nitrate inhibits fungal lanosterol 14α-demethylase (CYP51), disrupting ergosterol synthesis and causing fungal cell membrane damage.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Intravaginally, one suppository (100 mg miconazole nitrate) once daily at bedtime for 7 days or one suppository (200 mg) once daily for 3 days, combined with topical application of miconazole nitrate cream (2%) to the vulvar area twice daily for 7 days.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours, but can be prolonged to 30-40 hours in patients with hepatic impairment.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Primarily fecal (biliary) as unchanged drug and metabolites (~50-60%); renal excretion accounts for <20% of the dose, mostly as inactive metabolites.
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category A/B
Category C
Antifungal
Antifungal